Publications by authors named "U Conte"
Article Synopsis
- Relapsed or refractory multiple myeloma (RRMM) significantly affects patients' health-related quality of life (QOL), causing both physical and emotional burdens.
- An analysis of patient-reported outcomes (PROs) from the MagnetisMM-3 study on elranatamab showed early improvements in symptoms, such as reduced pain and better health outlooks for patients new to and those previously treated with BCMA therapy.
- Approximately 40.2% of BCMA-naive and 52.6% of BCMA-exposed patients reported feeling 'a little better' or 'much better' by Cycle 1, Day 15, indicating that elranatamab not only offers clinical benefits but may also enhance
Article Synopsis
- The ABRAZO trial studied how mutations in homologous recombination repair genes, specifically BRCA1/2, affect the effectiveness of the PARP inhibitor talazoparib in patients with those mutations.
- Out of 60 patients evaluated, a significant majority (97%) had BRCA1/2 mutations, with a high rate of concordance (95%) between germline and tumor mutations, and many exhibited homologous recombination deficiency (HRD).
- Non-BRCA mutations, such as TP53 and PIK3CA, are common in this population, but they do not seem to impact the sensitivity to talazoparib, which indicates the primary importance of BRCA mutations for treatment efficacy.
Elranatamab is a humanized B-cell maturation antigen (BCMA)-CD3 bispecific antibody. In the ongoing phase 2 MagnetisMM-3 trial, patients with relapsed or refractory multiple myeloma received subcutaneous elranatamab once weekly after two step-up priming doses. After six cycles, persistent responders switched to biweekly dosing.
View Article and Find Full Text PDFImportance: Preclinical data suggest that poly(ADP-ribose) polymerase (PARP) inhibitors have synergistic activity when combined with immune checkpoint inhibitors (ICIs); however, it is unknown which tumor types or molecular subtypes may benefit from this combination.
Objective: To investigate responses associated with the combination of avelumab and talazoparib in different tumor types and/or molecular subtypes.
Design, Setting, And Participants: In this phase 1b and 2 basket nonrandomized controlled trial, patients with advanced solid tumors were enrolled in the following cohorts: non-small cell lung cancer (NSCLC); DNA damage response (DDR)-positive NSCLC; triple-negative breast cancer (TNBC); hormone receptor-positive, human epidermal growth factor receptor 2 (ERBB2)-negative, DDR-positive breast cancer; recurrent, platinum-sensitive ovarian cancer (OC); recurrent, platinum-sensitive, BRCA1/2-altered OC; urothelial cancer; metastatic castration-resistant prostate cancer (mCRPC); DDR-positive mCRPC; and BRCA1/2- or ATM-altered solid tumors.